Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H34N2O.ClH.H2O |
Molecular Weight | 421.016 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
InChI
InChIKey=UEECHQPWQHYEDE-UHFFFAOYSA-N
InChI=1S/C24H34N2O.ClH.H2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H;1H2
DescriptionSources: http://www.rxlist.com/vascor-drug.htmCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569
Sources: http://www.rxlist.com/vascor-drug.htm
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569
Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It has inhibitory effects on both the slow calcium and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. It is used to treat hypertension (high blood pressure), angina (chest pain), sustained atrial fibrillation and tachyarrhythmia. The most common side effects were upper gastrointestinal complaints (nausea, dyspepsia or GI distress), diarrhea, dizziness, asthenia and nervousness. Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218 |
6.0 µM [IC50] | ||
Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218 |
|||
Target ID: 57582.0 Gene Symbol: KCNT1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16876206 |
1.0 µM [IC50] | ||
Target ID: Voltage and receptor operated calcium channels Sources: http://www.rxlist.com/vascor-drug.htm |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BEPRICOR Approved UseBepridil hydrochloride is indicated for the treatment of chronic stable angina (classic effort-associated angina). |
|||
Primary | BEPRICOR Approved UseBepridil is used to treat hypertension (high blood pressure) and to treat angina (chest pain). |
|||
Primary | BEPRICOR Approved UseIt is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina. |
|||
Primary | BEPRICOR Approved UseIt is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
806 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPRIDIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPRIDIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
38.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPRIDIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3875635 |
BEPRIDIL plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: |
Disc. AE: Weakness, Lightheadedness... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Sources: Lightheadedness (1 patient) Syncopal attack (1 patient) |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: |
Disc. AE: Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Electrocardiogram QTc interval prolonged (1 patient) Sources: |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: |
Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: Diarrhea (1 patient) Anorexia (1 patient) Bigeminy (1 patient) |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: |
Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (1 patient) Sources: Bradycardia (1 patient) |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: |
Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (grade 5, 1 patient) Sources: Bradycardia (1 patient) Electrocardiogram QTc interval prolonged (4 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Lightheadedness | 1 patient Disc. AE |
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: |
Syncopal attack | 1 patient Disc. AE |
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: |
Weakness | 2 patients Disc. AE |
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: |
Electrocardiogram QTc interval prolonged | 1 patient Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: |
Anorexia | 1 patient Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: |
Bigeminy | 1 patient Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: |
Diarrhea | 1 patient Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: |
Nausea | 1 patient Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: |
Bradycardia | 1 patient Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: |
Ventricular tachycardia | 1 patient Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: |
Bradycardia | 1 patient Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: |
Electrocardiogram QTc interval prolonged | 4 patients Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: |
Ventricular tachycardia | grade 5, 1 patient Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens. | 1992 Apr |
|
Biliary drug lithiasis: dipyridamole gallstones. | 1992 Nov 28 |
|
Antioxidant benzoylated flavan-3-ol glycoside from Celastrus orbiculatus. | 2001 Jan |
|
Electron spin resonance assessment of the antioxidant potential of medicinal plants. Part I. Contribution of anthocyanosides and flavonoids to the radical scavenging ability of fruit and herbal teas. | 2001 Jul-Aug |
|
DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. | 2001 Oct |
|
Scavenging of free radicals, antimicrobial, and cytotoxic activities of the Maillard reaction products of beta-lactoglobulin glycated with several sugars. | 2001 Oct |
|
Antioxidant activities of dioscorin, the storage protein of yam (Dioscorea batatas Decne) tuber. | 2001 Oct |
|
Identification and antioxidant activity of novel chlorogenic acid derivatives from bamboo (Phyllostachys edulis). | 2001 Oct |
|
Vasorelaxing and antioxidant constituents from Hernandia nymphaeifolia. | 2001 Oct |
|
Interaction of bepridil with the cardiac troponin C/troponin I complex. | 2001 Sep 28 |
|
Antagonistic effects of 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 on L-type Ca2+ channels and Na+/Ca2+ exchange in enterocytes from Atlantic cod (Gadus morhua). | 2002 Feb |
|
Role of Na(+)-Ca(2+) exchanger after traumatic or hypoxic/ischemic injury to spinal cord white matter. | 2002 Jan-Feb |
|
Free radical scavenging activity of red ginseng aqueous extracts. | 2002 Mar 20 |
|
Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. | 2003 Aug 15 |
|
A case of bepridil induced interstitial pneumonitis. | 2003 Dec |
|
Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP. | 2003 Dec 17 |
|
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
|
A case of sick sinus syndrome that developed torsades de pointes, pacing failure and sensing failure during administration of bepridil. | 2003 Sep |
|
Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. | 2004 Feb |
|
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. | 2004 Feb 20 |
|
Atrial fibrillatory frequency, atrial fibrillatory rate, or atrial cycle length--does it matter? | 2004 Jul 1 |
|
Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats. | 2004 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mtm/bepridil.html
Initial dose: 200 mg once a day.
Maintenance dose: 300-400 mg once a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24260442
In APP-overexpressing HEK293 cells lower Ab38, Ab40
and Ab42 generation was detected after Bepridil treatment (30 uM) for 16 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
52715
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
100000091268
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
3061
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
SUB13042MIG
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
4W2P15D93M
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
91725
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
235752
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
C47412
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
CHEMBL1008
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
DTXSID5040176
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
758390
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
SUB26026
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
DBSALT001436
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
74764-40-2
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | |||
|
m2422
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY | Merck Index | ||
|
Bepridil hydrochloride
Created by
admin on Mon Mar 31 17:53:44 GMT 2025 , Edited by admin on Mon Mar 31 17:53:44 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD